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ABSTRACT
This review summarises exciting recent and forthcoming
advances that will impact on the surgical management
of epilepsy in the near future. This does not cover the
current accepted diagnostic methodologies or surgical
treatments that are routinely practiced today. The
content of this review was derived from a PubMed
literature search, using the key words ‘Epilepsy Surgery’,
‘Neuromodulation’, ‘Neuroablation’, ‘Advances’,
between 2010 and November 2013.
INTRODUCTION
Despite advances in imaging and the accumulation
of neurological and surgical experience, the out-
comes for seizure freedom in epilepsy surgery have
not changed signiﬁcantly over the last 20 years.
Currently, 20–40% of patients with epilepsy are
considered refractory to medical treatment.1 Less
than 50% of these are candidates for focal resective
surgery, with rates of long-term seizure freedom
ranging from 30% to 60% depending on the oper-
ation.2 Some argue that this apparent lack of pro-
gress is a reﬂection of a lowered threshold to offer
surgery, and that with continued reﬁnement of
techniques, increasingly challenging cases are being
taken on. However, there is widespread agreement
that there remains great potential to improve non-
pharmacological management, to achieve either
better seizure control or complete seizure freedom.
There are three broad directions in which the
next major advances may occur. First, there is the
continued reﬁnement of the current methodology.
An improved hypothesis for the epileptogenic zone
(EZ), based on advanced presurgical evaluation,
including intracranial EEG, and thus, better patient
selection for cortical resections. This is probably
most relevant to sufferers of non-lesional extratem-
poral epilepsy, and is most likely to lead to
improvements in the rates of seizure freedom.
Next, there are improved surgical methods for
achieving a precisely targeted cortical or subcortical
resection. These can be grouped as neuroablative
techniques, and include disconnection of propaga-
tion pathways, and destruction of epileptogenic
foci. Neuroablation may be applied in the
treatment of focal and generalised epilepsy. Third,
neuromodulation may take a broader role, with the
possibility of improving quality of life and being a
useful palliation. This is most applicable to patients
who are currently not candidates for resective
epilepsy surgery, because their epilepsy arises from
eloquent cortex, is multifocal or generalised.
REFINEMENT OF CURRENT METHODOLOGY
The epileptogenic index
The purpose of presurgical evaluation is to deﬁne
the EZ, and to deﬁne the surrounding functional
deﬁcit zones. The notion of a single discrete area of
EZ is attractive in its simplicity, although the high
failure rate of resective surgery runs counter to
this. Rather, it is possible that in at least some cases
there are several structures involved in epileptogen-
esis, and a more comprehensive notion of the EZ
needs to be considered.
The characteristic electrophysiological pattern of
the EZ is the presence of high-frequency oscilla-
tions or ‘rapid discharges’. Bartolomei in 2008
introduced the concept of the ‘epileptogenic index
(EI)’, a novel quantitative measure that characterises
the epileptogenicity of brain structures recorded
with depth electrodes.3 The EI is based on spectral
and temporal factors, with statistically high values
corresponding to structures involved early in the
ictal process. They found that their measure of EI
effectively distinguished between mesial temporal
lobe epilepsy (MTLE) and lateral neocortical epi-
lepsy. Furthermore, in MTLE they found a statistic-
ally signiﬁcant correlation between the duration of
epilepsy and the number of structures disclosing
high EI values, suggesting that MTLE is a gradually
evolving process which progresses over time.
Visualisation of the EI, in 3D space as part of an
integrated multimodal model, is the obvious next
step. This would provide an alternative to the elec-
trical source imaging, but also provide a more
detailed, contoured brain map of seizure likelihood,
that could be used by the surgeon to stratify the
risk-beneﬁt ratio of cortical resection. Work is
already underway to make this a reality. David et al
in Grenoble, report the use of statistical parametric
mapping to visualise a quantiﬁcation of the seizure
onset zone.4 This has been applied to case studies
of insular epilepsy, and also group studies on
MTLE. This technique offers much promise in
future research and clinical practice, with obvious
applications in future guidance of stereoEEG
(SEEG) implantations, and in the delineation of
epileptogenic networks over time.
Advances in imaging
The rates of seizure freedom following resective
surgery in sufferers of non-lesional extratemporal
epilepsy remain poor.2 It is clear that better patient
selection is required in these cases, with improved
methods for imaging the EZ and guiding the
implantation of intracranial EEG. For some time
there has been interest in unmasking previously
occult structural lesions, using non-routine mag-
netic resonance (MR) sequences and voxel-based
morphometric analyses.5 There are also develop-
mental techniques, such as EEG-fMRI, which
require reﬁnement and further evaluation in clinical
practice.6
3D multimodality imaging is the simultaneous
display of different structural and functional
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datasets, tailored to individual patients. The feasibility of this
additional tool in a busy epilepsy surgery practice has been
demonstrated,7 and a prospective study is currently underway to
validate the usefulness of this in presurgical evaluation and sur-
gical management. Ultimately, improvements in the surgical out-
comes in this patient group will depend on better imaging,
including visualisation of electrical abnormalities in 3D, reliable
imaging integration and robust planning and implementation of
intracranial EEG (ﬁgure 1).
NEUROABLATION
There is an increasing trend in all forms of surgery towards min-
imally invasive techniques. This is most pertinent for neurosur-
gery, which often requires access to deep parts of the brain.
Accurate navigation to these areas without the need for signiﬁ-
cant brain retraction has been solved by the application of
stereotaxis. However, there remains the problem of how to
‘execute’ the surgery once instruments have been safely navi-
gated to their targets. This problem is best framed in the
context of epilepsy surgery with cortical resection following
SEEG. However, it is also possible to consider patients with hip-
pocampal sclerosis (HS), where even ‘selective’ amygdalohippo-
campectomies carry the risk of new cognitive deﬁcit.
There are a number of interesting alternatives to ‘execute’
lesioning at the site of the EZ or to cause a disconnection in a
minimally invasive way.
Radiofrequency (RF) thermocoagulation
There is much interest in complementing the technique of
SEEG with a therapeutic component to lesion cortex that is
sampled by the electrodes. The most obvious solution is by ther-
mocoagulation, using a RF generator connected to the electrode
contacts. A feasibility study from Lyons described this technique
in 2004, in 20 patients undergoing SEEG implantation.8
There are several beneﬁts with this technique. It builds on the
SEEG method that is well established, and proven to be safe and
reliable. It is well tolerated by the patient and does not require
general anaesthesia. Multiple sites can be lesioned, with real-
time clinical and electrophysiological feedback. Finally, this
method does not preclude the possibility of subsequent conven-
tional open surgery.
One disadvantage with this technique is that there is no real-
time feedback on the lesioning process with regards to local
temperatures. The operator relies on an abrupt decrease in
current to indicate coagulation of surrounding cortex. Also, RF
thermocoagulation is known to be an inherently imprecise
mode of thermal energy delivery, with theoretical risk to sur-
rounding structures.
Overall, the results for SEEG and thermocoagulation are
modest. A case series of 41 patients from the Lyons group
report that 20 (48.7%) experienced a signiﬁcant decrease in sei-
zures of at least 50%, and 21 (51.3%) did not beneﬁt from the
procedure.9 Only one patient was seizure-free following the pro-
cedure. There were no reports of worsening seizures. These
results suggest that RF thermocoagulation may be a low-risk,
palliative procedure, which can be considered as ﬁrst-line treat-
ment in patients undergoing SEEG to improve seizure control.
It seems that this technique is particularly suited to patients for
whom conventional surgery is contra-indicated or considered
too high risk, such as patients with deep epileptogenic heteroto-
pic nodules. However, a randomised controlled trial is needed
to determine which patient group exactly is most likely to
beneﬁt from RF thermocoagulation.
MR-guided focused ultrasound
Magnetic resonance-guided focused ultrasound surgery
(MRgFUS) is an accurate method of delivering high doses of
transcranial ultrasound energy to a discrete intracranial focal
point.10 The major historical barrier to this method was the
need to create a craniectomy window prior to treatment, to
prevent the ‘defocusing’ effect of the skull. However, recent
advances in phased array transducer technology have overcome
this defocusing effect, so that the treatment can be administered
in a ‘closed’ method without the need for conventional surgery.
The MRgFUS consists of a clinical 3 T MRI, with a transcra-
nial hemispheric array transducer that has 1024 ultrasound ele-
ments. The patient’s head is ﬁxed to the system in a stereotactic
frame and the transducer is ﬁlled with degassed water to allow
ultrasound waves to propagate toward the patient’s head.
Treatment planning is based on MRI, and MR thermometry is
used for target veriﬁcation during the procedure. The treatment
can be administered on an outpatient basis, and treatment effect
can be monitored by postoperative MRI (ﬁgure 2).
MRgFUS has previously been used to execute a selective
medial thalamotomy in the treatment of chronic neuropathic
pain.11 A US food and drug administration (FDA)-approved
phase I trial using MRgFUS thalamotomy in the treatment of
essential tremor has just been completed, and showed clinical
improvements in 15 patients.12 There are plans for further trials
in the treatment of metastatic brain tumour and Parkinson’s
disease.
MRgFUS has obvious and compelling attractions in epilepsy
surgery. There is the avoidance of any latency period or the risk
of secondary tumours with ionising radiation, which comes
with radiosurgery. There is the convenience of the treatment,
which does not involve any skin incision and, therefore, avoids
the surgical risks of infection, haemorrhage and wound dehis-
cence. There are no trajectory restrictions and, crucially, there is
near-real-time feedback of the lesioning effect, with MRI
thermometry.
The main concern with MRgFUS is the risk of inadvertent
heating of the skull base and critical structures such as cranial
nerves, which results from the ‘shadow’ effect of energy distal
to the focal point of the target. Cadaveric studies have yielded
techniques to minimise this collateral heating, by building into
the system software certain ‘no pass’ areas at the base of the
brain.13 However, this remains a signiﬁcant barrier (at present)
to the use of MRgFUS to lesion cortical and subcortical targets.
In theory, MRgFUS should evolve to become an important
treatment modality in epilepsy surgery, although it is important
to note there are no current cadaveric or clinical trials underway
to determine efﬁcacy.
Laser ablation
Ablation can also be achieved by MRI-guided laser interstitial
thermal therapy (MRgLITT). The commercially available
Visualase Thermal Therapy System combines a 15W 980 nm
diode laser and cooled laser application system with an image-
processing workstation. The applicator is inserted to reach the
target by a stereotactic method, and laser treatment is applied in
the MR scanner, with MR thermal imaging to visualise the
thermal ablation.
MRgLITT avoids the complications associated with radiosur-
gery. The ablation is more precise than that achieved with RF
thermocoagulation, and has reliable real-time feedback.
Furthermore, it appears to avoid the heating of the skull base
seen in ultrasound ablation. MRgLITT is a stereotactic surgical
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procedure, however, and therefore carries the surgical risks of
haemorrhage and infection.
This technology has recently received FDA clearance for abla-
tion in neurosurgery, and has previously been reported in the
treatment of brain metastases.14 A recent study describes the
initial use of this technique in the treatment of focal epilepsy in
ﬁve children.15 Lesions included a cingulate tuber, HS, hypo-
thalamic hamartoma (HH) and focal cortical dysplasia. There
were no complications, and early experience indicates that this
is a safe procedure. All patients were seizure-free at the time of
going to print, but follow-up is short and no meaningful infor-
mation can be drawn on long-term efﬁcacy at present. A pilot
study is currently underway, which will examine longer-term
seizure outcomes in 20 patients, It is our view that MRgLITT is
an exciting prospect, which is closer to clinical adoption in epi-
lepsy surgery than is MRgUS.
Stereotactic radiosurgery
Stereotactic radiosurgery (SRS) is a well-established technique
that uses focused ionising radiation to target deep-seated
lesions, sparing damage to surrounding tissue. The ionising radi-
ation breaks chemical bonds and results in the production of
free radicals. Ionising radiation can be generated by proton
beam accelerators and photon accelerators. The most widely
used sources of ionising radiation are photon accelerators, such
as Cyberknife and Gamma Knife.
The main advantage of SRS is that deep-seated and multiple
lesions can be treated without any surgical approach, avoiding
the inherent brain retraction/injury. The main disadvantages
include the latent period of efﬁcacy, collateral tissue injury sec-
ondary to radiation, and late-onset secondary malignancies.
Furthermore, the efﬁcacy of SRS in the treatment of different
conditions is not fully understood.
The anticonvulsant effects of SRS were ﬁrst observed in the
treatment of tumours and vascular lesions.16 SRS has also been
used as a disconnection technique in the treatment of general-
ised epilepsy by corpus callosotomy.17 Current interest is
centred mainly on the treatment of HHs and HS.
Hypothalamic hamartoma
SRS is increasingly being considered for the treatment of HH.
Treatment is best done in early childhood, before the develop-
ment of secondary generalised seizures, behavioural problems
and developmental delay. In selected cases, conventional open
surgery offers higher rates of seizure freedom, with the pooled
results from multiple studies showing seizure freedom rates
from open surgery at 50% and SRS at 30–40%.18–20 However,
depending on the characteristics and location of the HH, open
surgery may be considered too hazardous, and SRS is the
obvious alternative.21 SRS can also be used in conjunction with
open surgery in patients with large HH, if surgical debulking
leaves an unresectable residual epileptogenic intrahypothalamic
component.22
Hippocampal sclerosis
The use of SRS in the treatment of HS is controversial, since
conventional anterior temporal lobe resections offer a proven
and reliable treatment method. The theoretical advantage of
SRS is that the EZ may be lesioned in a selective way, without
injury to the lateral neocortex and corresponding neuropsycho-
logical complications.
The results of an early prospective multicentre trial on the
efﬁcacy of SRS in the treatment of MTLE were promising, with
seizure outcome at 2 years comparable to that of standard
surgery.23 No signiﬁcant cognitive deﬁcits were seen and, in
fact, 20% experienced some degree of cognitive improvement.
This compares favourably to standard surgery in which cogni-
tive impairment, particularly memory and word-ﬁnding, is
observed in 30%, and improvements are seen in 10–20%.24
A further multicentre prospective trial in the USA randomised
patients to SRS with high (24 Gy) or low (20 Gy) dose delivered
to the targets.25 At 3 years, seizure freedom was 77% in the
high dose and 59% in the low dose group. Again, the neuro-
psychological proﬁles compared favourably with results from
conventional surgery.
Figure 1 Volume rendering of cortex (grey) displayed in AMIRA with the following associated modalities: focal cortical dysplasia (red), ﬂuorodeoxy
glucose positron emission tomography (FDG-PET). hypometabolism (purple), hand motor fMRI (green), corticospinal tractography (blue), veins (cyan).
Figure 2 Commercially available magnetic resonance-guided
(MR-guided) focused ultrasound.10
Nowell M, et al. J Neurol Neurosurg Psychiatry 2014;85:1273–1279. doi:10.1136/jnnp-2013-307069 1275
Epilepsy
group.bmj.com on December 12, 2014 - Published by http://jnnp.bmj.com/Downloaded from 
Despite these results, there remain questions on the use of
SRS in MTLE. There are a number of published series that do
not give the same efﬁcacy rates in terms of seizure outcome.26–
28 Interpretation of these is complicated by differences in proto-
col, including dose, isodose centres or ‘shots’, and volume, but
the discordance in results should not be ignored.
The rate of optic radiation injury appears to be similar to that
seen in conventional open surgery, with homonymous ﬁeld
defects seen in 43–50%..23 25 This is a signiﬁcant risk in those
patients who become seizure-free and aspire to gain a driving
license, and may compare poorly with the results of open
surgery in which intraoperative visualisation of optic radiation
tractography may be employed29 and reduce the risk of visual
ﬁeld defects.
Finally, there are unique risks with SRS that are not seen with
conventional surgery, which may be related to the latent time
course. Progressive radiological changes are observed, with the
development of dose-dependent T2 hyperintensity, contrast
enhancement and vasogenic oedema, with mass effect at
9 months postoperatively, and peaking at 12 months. These
changes correspond to declines in complex partial seizures and
transient increases in auras; 70% of patients in the Barbaro
study also report new onset headaches postoperatively, although
the timing of these is not predictable.25
A National Institutes of Health (HIF)-funded multicentre ran-
domised controlled trial, the Radiosurgery or Open Surgery for
Epilepsy (ROSE) trial, was designed to answer these outstanding
questions. The trial randomised patients with MTLE to conven-
tional surgery or SRS, and was to compare seizure outcome,
cognitive outcome, quality of life and cost with an initial 3-year
follow-up. Unfortunately, recruitment to this trial has currently
stopped, with poor recruitment cited as the reason, and the con-
tinued funding of the work is in doubt. Without class 1 evi-
dence, the relative merits of these two treatment paradigms will
likely remain unclear.
Extratemporal epilepsies
There are no reports on the use of SRS in non-lesional extra-
temporal epilepsy. Certainly, the prerequisite need for intracra-
nial implantation to determine the EZ would negate the main
beneﬁt of SRS as a non-invasive procedure. However, since
other ablative methods have their own disadvantages, and so far
produce only modest results, SRS should not be completely dis-
missed as a possibility.
NEUROMODULATION
Functional neurosurgery refers to the surgical manipulation of
brain behaviour by the stimulation or removal of a population
of neurones. The most successful application of functional
neurosurgery is in the stimulation treatment of movement disor-
ders such as idiopathic Parkinson’s disease and essential tremor.
However, there are also applications for chronic pain disorders,
psychiatric disorders and epilepsy.
In this context, resective epilepsy surgery may be considered
under the umbrella term, functional neurosurgery, since it
involves the removal of a population of cells in the EZ.
However, conventionally functional neurosurgery in epilepsy
refers to the stimulation of cell populations, either through a
cranial nerve or directly through an implanted electrode.
Cranial nerve stimulation
Vagal nerve stimulation
Vagal nerve stimulation (VNS) is a well-established palliative
treatment for epilepsy, in patients who are not candidates for
resective surgery. Although VNS is unlikely to offer any advance
in epilepsy surgery, the elucidation of the mechanism of action
may have important consequences for other related treatments.
Current evidence points towards a deactivation of the nucleus of
the solitary tract, with widespread projections to the dorsal raphe
nucleus, locus coeruleus, hypothalamus, thalamus, amygdala and
hippocampus.30
Trigeminal nerve stimulation
Trigeminal nerve stimulation (TNS) is similar to VNS as it
involves the widespread stimulation of brain nuclei from an
afferent cranial nerve. Like VNS, the mechanism of action is not
well understood, but is thought to involve deactivation of the
nucleus of the solitary tract and the locus coeruleus.
TNS differs from VNS in several important ways. First, TNS
does not require surgical implantation, but can be delivered in a
ﬂexible and disposable way by application of electrodes to the
forehead to stimulate the supra-orbital nerves. This confers a
signiﬁcant advantage, offering patients a trial of treatment to
assess whether they are likely to be responders, without expos-
ure to the surgical risks of implantation. This also opens up the
opportunity for structural and functional MR studies in patients
undergoing TNS.
Second, the type of stimulation offered by TNS differs from
VNS, as it is high frequency and bilateral. In animal models, this
type of stimulation has been shown to be superior, with
increased magnitude of the seizure-reduction effect.31
A randomised controlled trial of TNS in drug-resistant epilepsy
has provided preliminary evidence that this is a safe and effective
treatment, with a signiﬁcant within-group improvement in
responder rate over time, deﬁned as a 50% reduction in seizure
frequency seen at 18 weeks.32 However, no signiﬁcant differ-
ences were seen between groups, due to the high responder rate
in the control group. No patients were rendered seizure-free with
this treatment. Large-scale phase III multicentre trials are
required to better understand the efﬁcacy of TNS, and also to
optimise treatment parameters. There are a number of variables
that can be manipulated, including frequency, amplitude and dur-
ation of stimulation. Despite this, the future role for TNS is likely
to be as a more tailored, safer alternative to VNS; it may offer the
twin beneﬁts of improved seizure control and improvements in
mood, but is unlikely to be a curative treatment.
Deep brain stimulation
There is a long history of interest in the use of deep brain stimu-
lation (DBS) for epilepsy control. The postulated mechanism of
action is by interrupting the propagation of seizure activity, or
by increasing the overall seizure threshold. Multiple targets have
been put forward, centred in and around the circuit of Papez.
Wu et al have provided an excellent summary of DBS targets
for the treatment of epilepsy33 (table 1).
The current results with DBS for the treatment of epilepsy
remain modest, even accounting for the difﬁcult patient group
with highly refractory epilepsy. Stimulation-related side effects
have been reported, most commonly with psychiatric distur-
bances and depression. There is also the possibility of habitu-
ation to long-term stimulation. Taken together, these
considerations have stimulated interest in a closed-loop, respon-
sive form of neurostimulation, which only administers stimula-
tion if triggered by seizure activity.
Closed-loop stimulation
The mechanism of action for closed-loop stimulation (CLS) is
similar to DBS, with a rising of seizure threshold or inhibition
1276 Nowell M, et al. J Neurol Neurosurg Psychiatry 2014;85:1273–1279. doi:10.1136/jnnp-2013-307069
Epilepsy
group.bmj.com on December 12, 2014 - Published by http://jnnp.bmj.com/Downloaded from 
of propagation. Targets for stimulation depend on the accurate
localisation of the EZ, which is a prerequisite to implantation.
This technique is most appropriate for patients with bitemporal
or multifocal epilepsy, with no more than two distinct EZ. It
also complements the technique of SEEG in cases where the EZ
is localised to eloquent cortex with considerable risks with
resection.
CLS relies on a robust form of automated seizure detection.
The most popular methods are based on analysis of EEG wave-
forms across the time domain, and include the following:
▸ line length tool, to detect changes in frequency
▸ area tool, to detect changes in signal amplitude
▸ half-wave tool, to detect the number of waves that exceed a
predetermined amplitude and duration.
There does not appear to be any single superior method for
seizure detection. Instead, a tailored approach seems most prom-
ising, using combinations of these tools modiﬁed and optimised
for individual patients.34
The RNS System Pivotal Clinical Investigation was a multi-
centre, randomised, double-blind sham stimulation controlled
trial in 191 patients with refractory epilepsy35 During the
initial 12-week blinded evaluation period, an initial implant-
ation effect was noted, with a reduction in seizure frequency in
the stimulation and sham groups of 34.2% and 25.2%,
respectively. This implantation effect was thought to be a
placebo effect, or an effect of the anaesthesia. However, as the
blinded period progressed, the improvement in seizure fre-
quency persisted and improved in the stimulation group to
41.5%, while improvement in the sham group fell by 9.4%. At
2 years median, seizure frequency was reduced by more than
50% with a responder rate of greater than 45% with stimula-
tion. Additionally, there were signiﬁcant improvements in
quality of life reported by patients receiving stimulation, via
the Quality of life in Epilepsy Inventory (QOLIE-89). Of par-
ticular interest, there was no reported worsening of neuro-
psychological conditions or mood disorders that were
commonly seen in conventional DBS.
Clearly, CLS requires more study, with outstanding questions
on seizure detection algorithms, targets and stimulation para-
meters, and long-term follow-up. However, this remains an
exciting prospect as a further treatment modality in refractory
epilepsy (ﬁgure 3).
Table 1 Table to show the summary of targets for DBS for the treatment of epilepsy
Controlled trial
Target Primary author Year Outcome
Anterior nucleus of the thalamus Fisher 2010 SANTE trial: 40.4% median seizure reduction
Cerebellum Van Buren 1978 69% seizure reduction in 80% patients
Wright 1984 Ineffective
Velasco 2005 >50% seizure reduction in 80% cases
Centromedian nucleus of the thalamus Fisher 1992 >50% seizure reduction in 80% cases
Velasco 2000 No significant difference
Hippocampus Tellez-Zenteno 2006 15% seizure reduction
Velasco 2007 >50% seizure reduction in all 9 patients
McLachlan 2010 33% seizure reduction
Caudate nucleus None (case reports only)
Subthalamic nucleus None (case reports only)
Corpus callosum/fornix None (animal models only)
Posterior hypothalamic mammillary nuclei None (case reports only)
Locus coeruleus None (case reports only)
Amended from Wu and Sharan.33
DBS, deep brain stimulation.
Figure 3 Closed-loop stimulation, with a depth electrode in the right hippocampus and a subdural grid over the inferior surface of the temporal
lobe.35
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Closed-loop local drug delivery
It is an attractive possibility that localised intracerebral delivery of
antiepileptic drugs (AED) can improve the efﬁcacy of pharmaco-
logical treatment of epilepsy, without systemic side effects36
Several groups are, therefore, engaged in research developing auto-
mated local drug delivery systems, comprising of seizure detection
technology coupled with intracranial delivery of AED37 The most
promising of these is the subdural hybrid neuroprosthesis (HNP),
described by Ludvig. Safety and efﬁcacy is currently being investi-
gated in rat and monkey models, but there remains some distance
to go before human clinical trials. Conceptually, this is closely
related to the closed-loop systems of neurostimulation. However,
this is arguably a more challenging path to take, requiring close
collaboration between the disciplines of microengineering, neuro-
pharmacology, neurophysiology and neurosurgery.
SUMMARY
There are several exciting avenues for further technological
advances in the surgical treatment of epilepsy surgery.
For patients undergoing open surgery, improving their out-
comes will depend on the stepwise reﬁnement of current meth-
odology, with advances in imaging epilepsy paramount. For
patients who are currently not candidates for open surgery,
increased delivery of treatment options by minimally invasive
techniques, either neuromodulatory or ablative in nature, is
likely to occur in the future.
Advances in neuromodulation will coincide with the elucida-
tion of the mechanism of action, and much work needs to be
done to reﬁne individual stimulation targets and stimulation
parameters. New neuromodulation techniques will also require
a robust evidence base for clinical indications, long-term efﬁcacy
and safety. As described, there are real difﬁculties in designing
trials for new epilepsy treatments where the ﬁndings of high
responder rates in control groups are a common feature and
compromise the interpretation of studies. One reason for
control responses is the well-documented placebo effect, which
is often present following functional sham surgery. Other pos-
sible causes, seen in drug trials and trials of new surgical treat-
ments, are related to the selection of the control group. The
group can be compromised by the phenomenon of ‘regression
towards the mean’, where inconsistency in seizure frequency,
and high initial seizure frequency, can later give the false impres-
sion of response rates in the control group as the study pro-
gresses. Additionally, it is not uncommon for patients in control
groups to have their medical treatment optimised, with a conse-
quent improvement in seizure control. Finally, outcome is a
complex term in epilepsy surgery, encompassing the interplay of
seizure freedom, seizure control, cognitive and surgical morbid-
ity and quality of life over a prolonged period of time. In the
future, large-scale and well-designed randomised controlled con-
trols will have to take these factors into account to provide the
evidence base for clinical implementation.
There is no consensus on the most promising technique for
neuroablation, and competition between different methods will
continue. In terms of clinical implementation, there are already
centres that use SRS and SEEG-guided RF routinely, while
MRgLITT is undergoing early clinical trials and MRgFUS
remains very much a research tool in epilepsy. One major disad-
vantage of neuroablation in general is that the size of the lesion-
ing is limited, and large, effective ‘resections’ can only be
achieved by the repeated lesioning of different contiguous
targets. For SEEG-guided RF and MRgLITT, this entails
repeated passage of hardware through the brain, with associated
risk of vascular injury. The precise targeting of individual propa-
gation pathways and epileptogenic foci is, therefore, likely to be
a largely palliative measure, with the eventual emergence of pre-
viously masked pathways and foci to continue seizure propaga-
tion following surgery. Unfortunately, this may be an
insurmountable limitation with neuroablation when compared
with conventional open surgery and cortical resection.
Finally, epilepsy surgery remains a signiﬁcantly underused
resource. It is often perceived as a treatment of last resort, with
patients typically referred after 20 years of seizures.38 This con-
trasts with the NICE (National Institute of Health and Care
Excellence) guidelines, which recommend referral to a tertiary
service if epilepsy is not controlled within 2 years (NICE clinical
guideline 137, 2012).39 This also runs counter to the evidence
that epilepsy surgery is a cost-effective treatment, with large
savings in seizure-free patients, as anticonvulsants and hospital
admissions are successfully eliminated.40 Perhaps the most
important advance for the future would be to increase aware-
ness in the general population, and education among health pro-
fessionals, on the safety and efﬁcacy of epilepsy surgery as an
early intervention in medically refractory focal epilepsy.
Early referrals to tertiary centres, coupled with the rigorous
application of systematic presurgical evaluation pathways in a
multidisciplinary environment, and with 3D multimodality
imaging, may be the simplest and surest way to advance epilepsy
surgery in the near future.
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